Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

What Was Tested

In this not phased trial, researchers set out to test Semaglutide.

Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).

It had two arms (groups): Surgery Arm (active comparator) and Medication Arm (active comparator).

Magnet System.

Semaglutide.

The registry classes the interventions as device and drug.

Who Took Part

Enrollment: 20 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).

The full record lists 4 inclusion and 6 exclusion criteria; among the exclusions: meets any of the contraindications for either treatment arm (surgery: magnet system; or medication: semaglutide), thereby prohibiting randomization; taking or treated with semaglutide, semaglutide-containing medications, or any other glp-1ra medication in the previous 12 months; pregnant, lactating or planning pregnancy during the clinical study and follow-up period.

How the Study Was Run

It was run as a randomized, crossover and open-label study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Semaglutide and the comparison in turn, acting as their own control.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-03-18 with completion listed for 2027-06.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Semaglutide in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.